These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 1583327

  • 1. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
    Casadevall A, Mukherjee J, Devi SJ, Schneerson R, Robbins JB, Scharff MD.
    J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327
    [Abstract] [Full Text] [Related]

  • 2. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
    Pirofski L, Lui R, DeShaw M, Kressel AB, Zhong Z.
    Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
    [Abstract] [Full Text] [Related]

  • 3. Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization.
    Mukherjee J, Casadevall A, Scharff MD.
    J Exp Med; 1993 Apr 01; 177(4):1105-16. PubMed ID: 8459205
    [Abstract] [Full Text] [Related]

  • 4. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.
    Devi SJ, Schneerson R, Egan W, Ulrich TJ, Bryla D, Robbins JB, Bennett JE.
    Infect Immun; 1991 Oct 01; 59(10):3700-7. PubMed ID: 1716613
    [Abstract] [Full Text] [Related]

  • 5. Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice.
    Nussbaum G, Anandasabapathy S, Mukherjee J, Fan M, Casadevall A, Scharff MD.
    Infect Immun; 1999 Sep 01; 67(9):4469-76. PubMed ID: 10456888
    [Abstract] [Full Text] [Related]

  • 6. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
    Beenhouwer DO, May RJ, Valadon P, Scharff MD.
    J Immunol; 2002 Dec 15; 169(12):6992-9. PubMed ID: 12471134
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.
    Maitta RW, Datta K, Lees A, Belouski SS, Pirofski LA.
    Infect Immun; 2004 Jan 15; 72(1):196-208. PubMed ID: 14688097
    [Abstract] [Full Text] [Related]

  • 8. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection.
    Fleuridor R, Lees A, Pirofski L.
    J Immunol; 2001 Jan 15; 166(2):1087-96. PubMed ID: 11145689
    [Abstract] [Full Text] [Related]

  • 9. Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development.
    May RJ, Beenhouwer DO, Scharff MD.
    J Immunol; 2003 Nov 01; 171(9):4905-12. PubMed ID: 14568972
    [Abstract] [Full Text] [Related]

  • 10. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
    Maitta RW, Datta K, Chang Q, Luo RX, Witover B, Subramaniam K, Pirofski LA.
    Infect Immun; 2004 Aug 01; 72(8):4810-8. PubMed ID: 15271943
    [Abstract] [Full Text] [Related]

  • 11. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
    Mukherjee J, Kozel TR, Casadevall A.
    J Immunol; 1998 Oct 01; 161(7):3557-68. PubMed ID: 9759877
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan.
    Maitta RW, Datta K, Pirofski LA.
    Vaccine; 2004 Sep 28; 22(29-30):4062-8. PubMed ID: 15364457
    [Abstract] [Full Text] [Related]

  • 13. Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.
    Brandt S, Thorkildson P, Kozel TR.
    Clin Diagn Lab Immunol; 2003 Sep 28; 10(5):903-9. PubMed ID: 12965925
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures.
    Oscarson S, Alpe M, Svahnberg P, Nakouzi A, Casadevall A.
    Vaccine; 2005 Jun 10; 23(30):3961-72. PubMed ID: 15917118
    [Abstract] [Full Text] [Related]

  • 15. Immunoelectronmicroscopic characterization of monoclonal antibodies (MAbs) against Cryptococcus neoformans.
    Todaro-Luck F, White EH, Reiss E, Cherniak R.
    Mol Cell Probes; 1989 Dec 10; 3(4):345-61. PubMed ID: 2482437
    [Abstract] [Full Text] [Related]

  • 16. The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies.
    Casadevall A, Scharff MD.
    J Exp Med; 1991 Jul 01; 174(1):151-60. PubMed ID: 1676047
    [Abstract] [Full Text] [Related]

  • 17. Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies.
    Todaro-Luck F, Reiss E, Cherniak R, Kaufman L.
    Infect Immun; 1989 Dec 01; 57(12):3882-7. PubMed ID: 2680986
    [Abstract] [Full Text] [Related]

  • 18. Unexpected diversity in the fine specificity of monoclonal antibodies that use the same V region gene to glucuronoxylomannan of Cryptococcus neoformans.
    McFadden DC, Casadevall A.
    J Immunol; 2004 Mar 15; 172(6):3670-7. PubMed ID: 15004170
    [Abstract] [Full Text] [Related]

  • 19. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.
    Zhang H, Zhong Z, Pirofski LA.
    Infect Immun; 1997 Apr 15; 65(4):1158-64. PubMed ID: 9119446
    [Abstract] [Full Text] [Related]

  • 20. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals.
    Deshaw M, Pirofski LA.
    Clin Exp Immunol; 1995 Mar 15; 99(3):425-32. PubMed ID: 7882565
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.